KUALA LUMPUR: Malaysian Genomics Resource Centre Bhd's (MGRC) subsidiary MGRC Therapeutics Sdn Bhd has formed a partnership with Korean healthcare solutions provider Dx&Vx Co Ltd (DXVX) for genomic testing services.
MGRC said the companies aim to drive the development and supply of advanced genomic testing services, setting new benchmarks in the field of genomic analysis and digital healthcare.
Under the partnership, MGRC Therapeutics will leverage its extensive expertise in genomics and biopharmaceuticals to support the operational and technical aspects of the genomic testing services.
Concurrently, DXVX will provide its cutting-edge "GenomeCheck" solutions and technical consultancy to enhance the service offerings.
The partnership is expected to significantly enhance the reach and effectiveness of genomic testing services, addressing the growing demand for sophisticated healthcare solutions.
MGRC executive chairman Azri Azerai said the collaboration is a significant step towards entering the global market with genomic analysis services, aligning with both companies' strategic goals to expand their reach and impact.
"Partnering with DXVX is a strategic move that will elevate our genomic testing services to new heights.
"By combining our strengths, we are set to enhance the precision and accessibility of genomic analysis, making significant strides in personalised medicine.
"This collaboration reinforces our dedication to innovation and excellence in the healthcare sector," he added.
DXVX chief executive officer Kyu-chan Kwon said the collaboration marks a pivotal moment for the company, as it aims to establish a strong foothold in the Asian and global markets.
He noted that genomic analysis is a cornerstone of the company's "Healthcare 4.0" vision.
"Through this collaboration, we are set to expand our genomic testing services and digital healthcare solutions, ultimately improving patient outcomes and advancing the field of preventive care," he said.
